Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

NCT01168895 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection
Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)
DRUG: Cipro Inhale (Ciprofloxacin, BAYQ3939)

Sponsor

Bayer